Alisertib
Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity[1][2][3].
Product Specifications
CAS Number
1028486-01-2
Product Name Alternative
MLN 8237
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Apoptosis; Aurora Kinase; Autophagy
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Alisertib.html
Purity
99.84
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C(C=C1OC)NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C5=C(C=CC=C5F)OC)O
Molecular Formula
C27H20ClFN4O4
Molecular Weight
518.92
Precautions
H302, H312, H332
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Aurora A; Aurora B
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD21 (Mature B-Cell & Follicular Dendritic Cell Marker) (rCR2/1952), 0.2mg/mL
Cdk2 / p34cdc2 Serine-Threonine Kinase (AN4.3), CF594 conjugate, 0.1mg/mL
MUC18 / CD146 / MCAM (Melanoma Cell Adhesion Molecule) (rMUC18/1130), CF568 conjugate, 0.1mg/mL
